Science
Study Title
Synairgen to start trial of SNG001 in COVID-19 imminently
Publication
Synairgen
Author(s)
Synairgen plc
Abstract
Southampton, UK – 18 March 2020: Synairgen plc (LSE: SNG), the respiratory drug discovery and development company, today announces that it has received expedited approvals from the Medicines and Healthcare products Regulatory Agency (MHRA) and Health Research Authority (HRA) to conduct a trial of SNG001 (inhaled formulation of interferon-beta-1a) in COVID-19 patients to potentially assist with the global outbreak of the virus.
Date
March 18, 2020
View study
